Categories: विदेश

BRIEF-Eisai And Biogen Announce U.S. Availability Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection Maintenance Dose For Treatment Of Early Alzheimer’S Disease

Oct 6 (Reuters) – * EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Inkhabar webdesk

Share
Published by Inkhabar webdesk

Recent Posts

FuboTV names Disney's Bowen CEO, removes veteran Gandler

July 9 (Reuters) - Streaming firm FuboTV on Thursday named Disney executive Alisa Bowen as…

2 hours ago

FuboTV names Disney's Bowen CEO, removes veteran Gandler

July 9 (Reuters) - Streaming firm FuboTV on Thursday named Disney executive Alisa Bowen as…

3 hours ago

FuboTV names Disney's Bowen CEO, removes veteran Gandler

July 9 (Reuters) - Streaming firm FuboTV on Thursday named Disney executive Alisa Bowen as…

3 hours ago

If you have diabetes and are going on holiday, tips to bear in mind

Berlin (dpa) – After a tiring day of travelling, most people look forward to collapsing…

5 hours ago

iHeart agrees to resolve US probe into airplay practices

WASHINGTON, July 9 (Reuters) -    IHeartMedia resolved a Federal Communications Commission probe into allegations…

6 hours ago

iHeart agrees to resolve US probe into airplay practices

WASHINGTON, July 9 (Reuters) -    IHeartMedia resolved a Federal Communications Commission probe into allegations…

6 hours ago